PMVP

PMV Pharmaceuticals Inc

1.30

Oct 22 • 3:59 PM ET -0.06 (-4.04%)

1.30

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Micro NASD

Peers: BDTX APRE ZNTL KURA FHTX TNGX RLAY IDYA ERAS VSTM

| Held by: VTI VXF IWC BUSM BTEC AVTM

Scroll to Statements

Index	-
Market Cap	98.55M
Enterprise Value	19.34M
Income	-75.22M
Sales	0.00M
Book/sh	1.34
Cash/sh	1.05
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	54
IPO	Sep 25, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.98
P/C	1.24
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	7.70
Current Ratio	7.70
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-1.41
EPS next Y	-0.90
EPS next Q	-0.34
EPS this Y	19.26%
EPS next Y	25.10%
EPS next 5Y	21.53%
EPS past 3/5Y	2.74% -13.98%
Sales past 3/5Y	- -
EPS Y/Y TTM	9.38%
Sales Y/Y TTM	-
EPS Q/Q	16.92%
Sales Q/Q	-
Earnings	Aug 14 BMO
EPS/Sales Surpr.	12.26% -

Insider Own	6.90%
Insider Trans	0.00%
Inst Own	41.94%
Inst Trans	-3.76%
ROA	-64.04%
ROE	-70.93%
ROIC	-105.20%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-10.12%
SMA50	-5.49%
SMA200	0.55%
Trades

Shs Outstand	75.51M
Shs Float	70.30M
Short Float	3.97%
Short Ratio	4.23
Short Interest	2.79M
52W High	1.91 -31.68%
52W Low	1.02 27.94%
Volatility	7.34% 9.53%
ATR (14)	0.12
RSI (14)	44.69
Beta	1.48
Rel Volume	0.19
Avg Volume	661.23K
Volume	128,615

Perf Week	1.16%
Perf Month	-4.74%
Perf Quarter	5.24%
Perf Half Y	-8.74%
Perf YTD	4.40%
Perf Year	-15.26%
Perf 3Y	-12.42%
Perf 5Y	-94.68%
Perf 10Y	-
Recom	1.00
Target Price	4.20
Prev Close	1.36
Price	1.30
Change %	-4.04%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-08-26	Initiated	Ladenburg Thalmann	Buy	$3
Nov-08-24	Upgrade	Oppenheimer	Perform → Outperform	$6
May-13-24	Initiated	Craig Hallum	Buy	$6
Apr-12-24	Initiated	Jefferies	Buy	$5
Dec-27-23	Initiated	Ladenburg Thalmann	Buy	$7
Mar-02-22	Upgrade	Oppenheimer	Perform → Outperform	$30
Sep-22-21	Upgrade	Goldman	Neutral → Buy	$35 → $43
Aug-19-21	Initiated	Oppenheimer	Perform
Aug-02-21	Initiated	Guggenheim	Buy	$56
Jul-29-21	Initiated	H.C. Wainwright	Buy	$63
Oct-20-20	Initiated	Goldman	Neutral	$34
Oct-20-20	Initiated	Evercore ISI	Outperform	$60
Oct-20-20	Initiated	Cowen	Outperform
Oct-20-20	Initiated	BofA Securities	Buy	$42

Show Previous Ratings

Oct-05-26 08:00AM	PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors (GlobeNewswire)
Sep-08-26 08:00AM	PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer (GlobeNewswire)
Aug-31-26 11:03PM	PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities (GlobeNewswire) +6.61%
04:02PM	PMV Pharma Announces Proposed Public Offering of Securities (GlobeNewswire)
04:01PM	PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial (GlobeNewswire)
08:00AM	Loading…
Aug-14-26 08:00AM	PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights (GlobeNewswire)
May-12-26 08:00AM	PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights (GlobeNewswire)
Apr-22-26 08:00AM	PMV Pharmaceuticals Announces Board Chair Transition (GlobeNewswire)
Mar-06-26 08:00AM	PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights (GlobeNewswire) +7.19%
Feb-26-26 08:00AM	New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors (GlobeNewswire) +22.32%
Nov-12-25 08:00AM	PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights (GlobeNewswire) +6.77%
Oct-24-25 11:39AM	PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation (GlobeNewswire)
Oct-13-25 04:01PM	PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire) +7.58%
Sep-10-25 03:10PM	Small-Cap PMV Pharmaceuticals Cancer Drug Shows Confirmed Responses In 8 Tumor Types (Benzinga) -20.63%
07:00AM	PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation (GlobeNewswire)
08:42AM	Loading…
Aug-07-25 08:42AM	PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights (GlobeNewswire)
May-23-25 04:05PM	PMV Pharmaceuticals to Participate at Upcoming Investor Conferences (GlobeNewswire)
May-09-25 08:00AM	PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights (GlobeNewswire)
Mar-05-25 09:55AM	Here's Why PMV Pharmaceuticals (PMVP) Looks Ripe for Bottom Fishing (Zacks) +6.20%
Mar-03-25 08:00AM	PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights (GlobeNewswire)
Feb-11-25 08:00AM	PMV Pharmaceuticals to Participate at Upcoming Investor Conferences (GlobeNewswire)
Nov-07-24 08:00AM	PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results (GlobeNewswire) +7.23%
Oct-23-24 08:00AM	PMV Pharmaceuticals Provides a Progress Update on PYNNACLE Clinical Trial (GlobeNewswire) -6.43%
Aug-08-24 08:00AM	PMV Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Progress Update on PYNNACLE Clinical Trial (GlobeNewswire)
Jun-03-24 09:55AM	Here's Why PMV Pharmaceuticals (PMVP) Could be Great Choice for a Bottom Fisher (Zacks)
May-30-24 07:00AM	PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in June (GlobeNewswire)
May-29-24 07:00AM	Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator (GlobeNewswire) -10.45%
May-09-24 01:54PM	PMVP Stock Earnings: PMV Pharma Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights (GlobeNewswire)
Mar-27-24 08:00AM	PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors (GlobeNewswire)
04:01PM	Loading…
Mar-18-24 04:01PM	PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer (GlobeNewswire) -5.11%
Mar-01-24 10:21AM	PMV Pharmaceuticals Inc (PMVP) Reports Full Year 2023 Financial Results (GuruFocus.com)
Feb-29-24 04:01PM	PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights (GlobeNewswire)
Feb-26-24 08:00AM	PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference (GlobeNewswire) +7.78%
Jan-18-24 04:01PM	PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway (GlobeNewswire) -5.76% -10.56%
Jan-05-24 04:01PM	PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development (GlobeNewswire) -5.94%
Nov-09-23 09:41AM	PMV Pharmaceuticals Inc (PMVP) Reports Q3 2023 Financial Results and Corporate Updates (GuruFocus.com)
08:00AM	PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire)
Oct-16-23 09:35AM	PMV Pharmaceuticals, Inc. (PMVP) Loses -70.19% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -11.00%
Oct-12-23 12:30PM	PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation (GlobeNewswire) -47.58%
Oct-11-23 12:00PM	PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL Webinar (GlobeNewswire) -26.01%
Oct-06-23 09:55AM	Wall Street Analysts See a 239.26% Upside in PMV Pharmaceuticals, Inc. (PMVP): Can the Stock Really Move This High? (Zacks) +6.62%
Sep-20-23 04:05PM	PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire) +9.62%
Aug-30-23 09:55AM	Wall Street Analysts Think PMV Pharmaceuticals, Inc. (PMVP) Could Surge 182.64%: Read This Before Placing a Bet (Zacks)
Aug-29-23 09:55AM	PMV Pharmaceuticals, Inc. (PMVP)'s Technical Outlook is Bright After Key Golden Cross (Zacks)
Aug-09-23 08:00AM	PMV Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire) +27.69%
Jun-06-23 04:01PM	PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare Conference (GlobeNewswire) +7.56%
May-10-23 08:00AM	PMV Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire) +8.33%
Apr-14-23 11:51AM	We Think PMV Pharmaceuticals (NASDAQ:PMVP) Can Afford To Drive Business Growth (Simply Wall St.)
Mar-01-23 08:00AM	PMV Pharmaceuticals Reports Full Year 2022 Financial Results and Corporate Highlights (GlobeNewswire) -14.15%
Feb-28-23 04:05PM	PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in March (GlobeNewswire)
Dec-08-22 09:55AM	Does PMV Pharmaceuticals, Inc. (PMVP) Have the Potential to Rally 267% as Wall Street Analysts Expect? (Zacks)
Nov-22-22 08:00AM	PMV Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference (GlobeNewswire) +5.02%
Nov-17-22 06:18PM	15 Most Shorted Stocks Right Now (Insider Monkey)
Nov-08-22 08:00AM	PMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights (GlobeNewswire)
Nov-05-22 09:39AM	We Think PMV Pharmaceuticals (NASDAQ:PMVP) Can Afford To Drive Business Growth (Simply Wall St.)
Nov-04-22 08:00AM	PMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of Directors (GlobeNewswire)
Oct-11-22 12:00PM	PMV Pharmaceuticals, Inc. (PMVP) Upgraded to Buy: Here's What You Should Know (Zacks)
Sep-23-22 09:19AM	10 Most Shorted Stocks in September (Insider Monkey)
Aug-09-22 08:00AM	PMV Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights (GlobeNewswire) -8.06%
Jul-19-22 09:26AM	10 Most Shorted Stocks to Watch in July (Insider Monkey) +5.81%
Jul-18-22 10:47AM	PMV Pharma, Merck Ink Clinical Trial Collaboration For Combination Study In Solid Tumors (Benzinga) -9.52%
08:00AM	PMV Pharmaceuticals Announces a Clinical Trial Collaboration with Merck to Evaluate PC14586 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors (GlobeNewswire)
Jun-08-22 08:00AM	PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare Conference (GlobeNewswire) -5.71%
Jun-07-22 12:00PM	PMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a p53 Y220C Mutation (GlobeNewswire) -21.70%
May-29-22 08:26AM	We're Not Very Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Rate (Simply Wall St.)
May-26-22 05:05PM	PMV Pharmaceuticals Announces Initial PC14586 Phase 1 Clinical Data to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) +16.05%
May-20-22 03:04PM	Pennsylvania Biotech Center's economic impact grows to $7B as it expands in Bucks County, report finds (American City Business Journals)
May-10-22 07:30AM	PMV Pharmaceuticals Reports First Quarter 2022 Financial Results and Corporate Highlights (GlobeNewswire) +9.66%
Apr-27-22 10:30AM	PMV Pharmaceuticals to Present PC14586 Phase 1 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Mar-01-22 07:15AM	PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights (GlobeNewswire) +5.11%
Feb-28-22 08:00AM	PMV Pharmaceuticals to Participate in the 42nd Annual Cowen Health Care Conference (GlobeNewswire)
Feb-03-22 08:00AM	PMV Pharmaceuticals to Participate in the Guggenheim Healthcare Talks 2022 Oncology Day (GlobeNewswire)
Jan-12-22 12:20PM	Do Hedge Funds Love PMV Pharmaceuticals, Inc. (PMVP)? (Insider Monkey)
Jan-06-22 08:00AM	PMV Pharma Announces Changes to its Board of Directors (GlobeNewswire) -16.31%
Dec-20-21 10:28AM	We're Hopeful That PMV Pharmaceuticals (NASDAQ:PMVP) Will Use Its Cash Wisely (Simply Wall St.)
Nov-22-21 08:00AM	PMV Pharma to Present at the Evercore ISI 4th Annual HealthCONx Conference (GlobeNewswire)
Nov-12-21 07:15AM	PMV Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Highlights (GlobeNewswire)
Oct-05-21 11:33AM	Pmv Pharmaceuticals Insider Trades $440K In Company Stock (Benzinga)
Sep-27-21 09:26PM	Goldman Sachs: Buy These 2 Stocks Before They Jump 40% (or More) (TipRanks)
Sep-09-21 08:00AM	PMV Pharmaceuticals Appoints Tim Smith as Senior Vice President, Head of Corporate Development (GlobeNewswire)
Sep-02-21 08:00AM	PMV Pharmaceuticals to Present at the Morgan Stanley 19th Annual Global Healthcare Conference (GlobeNewswire)
Aug-13-21 08:00AM	PMV Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights (GlobeNewswire)
Jul-19-21 06:19PM	Where Do Hedge Funds Stand On PMV Pharmaceuticals, Inc. (PMVP)? (Insider Monkey)
Jun-23-21 05:38AM	We're Hopeful That PMV Pharmaceuticals (NASDAQ:PMVP) Will Use Its Cash Wisely (Simply Wall St.)
Jun-09-21 08:00AM	PMV Pharmaceuticals Announces Participation at the Bank of America Securities 2021 Napa Biopharma Virtual Conference (GlobeNewswire)
Jun-03-21 08:00AM	PMV Pharmaceuticals Announces Participation at the Goldman Sachs Annual Healthcare Conference (GlobeNewswire)
May-14-21 08:00AM	PMV Pharmaceuticals Reports First Quarter 2021 Financial Results and Corporate Highlights (GlobeNewswire) +10.54%
May-05-21 08:00AM	PMV Pharmaceuticals Announces Participation at the Bank of America Healthcare Conference (GlobeNewswire)
Apr-10-21 01:31PM	PMV Pharma Presents Late-Breaking Preclinical Data on Lead Product Candidate PC14586 at the American Association for Cancer Research Annual Meeting 2021 (GlobeNewswire)
Apr-06-21 08:00AM	PMV Pharma Strengthens Board of Directors with Appointment of Dr. Charles Baum (GlobeNewswire)
Mar-10-21 04:31PM	PMV Pharmaceuticals Announces Presentation of PC14586 Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021 (GlobeNewswire) +12.26%
Mar-03-21 04:01PM	PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights (GlobeNewswire)
Feb-16-21 08:00AM	PMV Pharma Appoints p53 Pioneer Dr. Guillermina Lozano to Scientific Advisory Board (GlobeNewswire) -9.57%
Dec-25-20 03:44AM	We're Not Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn (Simply Wall St.)
Dec-16-20 03:19PM	Is PMVP A Good Stock To Buy Now? (Insider Monkey)
Nov-24-20 05:00PM	PMV Pharmaceuticals to Present at Evercore ISI 3rd Annual HealthCONx Conference (GlobeNewswire) +8.67%
Nov-23-20 08:00AM	PMV Pharma Doses First Patient in Phase 1/2 Study of PC14586, a First-in-Class Precision Oncology Therapy That Targets Mutant p53 (GlobeNewswire)
Nov-13-20 08:00AM	PMV Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights (GlobeNewswire) -5.50%
Oct-13-20 08:00AM	PMV Pharma Granted FDA Fast Track Designation of PC14586 for the Treatment of Advanced Cancer Patients that have Tumors with a p53 Y220C Mutation (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mack David Henry	President and CEO	Oct 27 '25	Option Exercise	1.37	220,643	302,281	451,109	Oct 29 04:11 PM
ORBIMED ADVISORS LLC	10% Owner	Oct 23 '25	Sale	1.52	1,000,000	1,520,000	4,975,291	Oct 27 05:19 PM
OrbiMed Private Investments V,	Shareholder	Oct 23 '25	Proposed Sale	1.52	1,000,000	1,520,000		Oct 23 06:39 PM

PMV Pharmaceuticals, Inc. is a precision oncology company, which engages in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The company was founded by Arnold J. Levine, David Henry Mac, and Thomas E. Shenk in March 2013 and is headquartered in Princeton, NJ.

Co-FounderDr. David H. Mack Ph.D.

Co-FounderDr. Arnold J. Levine Ph.D.

General CounselMr. Robert Ticktin J.D.

Chief Development OfficerDr. Deepika Jalota Pharm.D.

CFO & Principal Financial & Accounting OfficerMr. Michael Carulli

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PMVP

PMV Pharmaceuticals Inc

Upgrade your Finviz experience